Immuneel is advancing access to breakthrough cancer therapies in India, for India and the world.
Cell, gene, and immunotherapies are transforming the landscape of cancer care, bringing real hope to millions worldwide. However, in the few countries where these therapies are available, they remain prohibitively expensive and largely inaccessible.
Immuneel, led by a group of healthcare visionaries across US & India, is making cell therapies affordable and accessible in India, for India and beyond.
Using immune cells to fight cancer
Immuneel is pioneering cell and gene therapies such as Chimeric Antigen Receptor T cell therapy (CAR-T cell therapy) in India. CAR-T cell therapies use genetically modified human immune cells to fight cancer.
As transformative cell and gene therapies emerge globally, Immuneel is driving efforts to make them accessible in India and contribute to advancing these innovations worldwide.
Ending the wait for millions
Despite India’s strong foundation of scientific talent, cutting-edge research, expert clinicians, and modern healthcare infrastructure, access to next-generation cancer therapies remains limited. Immuneel is addressing this critical gap, not only to serve India’s growing cancer burden, but also to contribute meaningfully to the global cell and gene therapy landscape.
With its integrated approach and innovation-driven mindset, Immuneel is uniquely positioned to deliver advanced treatment options, expand access, and improve outcomes for patients everywhere.
A Success Story
Calling for partners, today
Partners are intrinsic to Immuneel’s plans to make a difference. We are collaborating with the world’s best to develop and deliver high quality cell therapies affordably. Our talented team, partners and investors are powering our crusade.
Join us.
What’s happening?
Recognitions for Immuneel
Wins ‘Most Promising Cell & Gene Therapy Startup in APAC’ at the Asia Pacific Cell & Gene Therapy Excellence Awards 2023, IMAPAC, ‘Innovation in Cell and Gene Therapy’s’ at the Endpoints 11 Awards event, ‘Innovation in Cell and Gene Therapy’ at BioPharma Honours 2023 & ‘CGCS Pioneers Award’ at International Cell & Gene Therapy China Summit & Exhibition 2024.
